Hepatic volume changes induced by radioembolization with 90Y resin microspheres. A single-centre study

  • Hojjat Ahmadzadehfar
  • Carsten Meyer
  • Samer Ezziddin
  • Amir Sabet
  • Anja Hoff-Meyer
  • Marianne Muckle
  • Timur Logvinski
  • Hans Heinz Schild
  • Hans Jürgen Biersack
  • Kai Wilhelm
Original Article



Lobar radioembolization (RE) of the liver can result in reduction in volume of the ipsilateral lobe as well as hypertrophy of the contralateral lobe. Theoretically, hypertrophy of the contralateral liver lobe after RE could increase the chance of a successful liver resection, especially in patients with limited liver function reserve. The aim of this preliminary study was to evaluate the early effects of RE with resin microspheres on the volumes of the liver lobes and spleen.


We retrospectively investigated 24 patients (12 women, 44–78 years old) with different types of cancer and liver-dominant metastatic disease who had undergone RE of the liver with resin microspheres. Changes in the volumes of the liver lobes and spleen were quantified by CT before and about 4 to 8 weeks after treatment.


Of the 24 patients, 17 suffered from metastases in both liver lobes (group A) and 7 had metastases only in the right liver lobe (group B). The patients in the group A underwent sequential treatment starting with the right liver lobe. The median administered dose was 1.75 GBq. RE was associated with a median increase in volume of the left liver lobe of 34 % (P < 0.001) and a median decrease in volume of the right liver lobe of 11 % (P = 0.03). The volume of the spleen showed a median increase of 17 % (P = 0.01). Separate analysis of the two groups showed a median increases in volume of the left liver lobe of 30 % (P = 0.001) in group A and 70 % (P = 0.01) in group B. There was no correlation between the injected dose and the volume alteration (r = 0.1–0.3).


RE of the right liver lobe with resin microspheres caused a significant increase in the volume of the left liver lobe. This may allow liver resection in patients with metastases in the right liver lobe and a small left liver lobe.


Radioembolization Resin microspheres Liver metastases SIRT 


Conflicts of interest



  1. 1.
    Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251–78. doi:10.1097/01.RVI.0000233785.75257.9A.PubMedCrossRefGoogle Scholar
  2. 2.
    Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818–25. discussion 25–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology. 2011;54:868–78. doi:10.1002/hep.24451.PubMedCrossRefGoogle Scholar
  4. 4.
    Mulcahy MF, Lewandowski RJ, Ibrahim SM, et al. Radioembolization of colorectal hepatic metastases using yttrium-90 microspheres. Cancer. 2009;115:1849–58. doi:10.1002/cncr.24224.PubMedCrossRefGoogle Scholar
  5. 5.
    Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg. 2008;247:1029–35. doi:10.1097/SLA.0b013e3181728a4500000658-200806000-00017.PubMedCrossRefGoogle Scholar
  6. 6.
    Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65:412–25. doi:10.1016/j.ijrobp.2005.12.051.PubMedCrossRefGoogle Scholar
  7. 7.
    Ahmadzadehfar H, Biersack HJ, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med. 2010;40:105–21. doi:10.1053/j.semnuclmed.2009.11.001.PubMedCrossRefGoogle Scholar
  8. 8.
    Gaba RC, Lewandowski RJ, Kulik LM, et al. Radiation lobectomy: preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Ann Surg Oncol. 2009;16:1587–96. doi:10.1245/s10434-009-0454-0.PubMedCrossRefGoogle Scholar
  9. 9.
    Seidensticker R, Seidensticker M, Damm R, et al. Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus whole liver approach. Cardiovasc Intervent Radiol. 2012;35:1109–18. doi:10.1007/s00270-011-0295-7.PubMedCrossRefGoogle Scholar
  10. 10.
    Gulec SA, Pennington K, Hall M, Fong Y. Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections. World J Surg Oncol. 2009;7:6. doi:10.1186/1477-7819-7-6.PubMedCrossRefGoogle Scholar
  11. 11.
    Jakobs TF, Saleem S, Atassi B, et al. Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres. Dig Dis Sci. 2008;53:2556–63. doi:10.1007/s10620-007-0148-z.PubMedCrossRefGoogle Scholar
  12. 12.
    Sabet A, Ahmadzadehfar H, Muckle M, et al. Significance of oral administration of sodium perchlorate in planning liver-directed radioembolization. J Nucl Med. 2011;52:1063–7. doi:10.2967/jnumed.110.083626.PubMedCrossRefGoogle Scholar
  13. 13.
    Ahmadzadehfar H, Sabet A, Biermann K, et al. The significance of 99mTc-MAA SPECT/CT liver perfusion imaging in treatment planning for 90Y-microsphere selective internal radiation treatment. J Nucl Med. 2010;51:1206–12. doi:10.2967/jnumed.109.074559.PubMedCrossRefGoogle Scholar
  14. 14.
    Ahmadzadehfar H, Mohlenbruch M, Sabet A, et al. Is prophylactic embolization of the hepatic falciform artery needed before radioembolization in patients with (99m)Tc-MAA accumulation in the anterior abdominal wall? Eur J Nucl Med Mol Imaging. 2011;38:1477–84. doi:10.1007/s00259-011-1807-z.PubMedCrossRefGoogle Scholar
  15. 15.
    Ahmadzadehfar H, Muckle M, Sabet A, Wilhelm K, Kuhl C, Biermann K. The significance of bremsstrahlung SPECT/CT after yttrium-90 radioembolization treatment in the prediction of extrahepatic side effects. Eur J Nucl Med Mol Imaging. 2012;39:309–15. doi:10.1007/s00259-011-1940-8.CrossRefGoogle Scholar
  16. 16.
    Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50 Suppl 1:122S–50. doi:10.2967/jnumed.108.057307.PubMedCrossRefGoogle Scholar
  17. 17.
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47. doi:10.1016/j.ejca.2008.10.026.PubMedCrossRefGoogle Scholar
  18. 18.
    Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–81. doi:10.1016/S1053-4296(03)00031-6.PubMedCrossRefGoogle Scholar
  19. 19.
    Denys A, Prior J, Bize P, Duran R, De Baere T, Halkic N, et al. Portal vein embolization: what do we know? Cardiovasc Intervent Radiol. 2012;35:999–1008. doi:10.1007/s00270-011-0300-1.PubMedCrossRefGoogle Scholar
  20. 20.
    Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235:759–66.PubMedCrossRefGoogle Scholar
  21. 21.
    Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG. Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg. 2003;197:29–37. doi:10.1016/S1072-7515(03)00230-8.PubMedCrossRefGoogle Scholar
  22. 22.
    Howlader M, Heaton N, Rela M. Resection of liver metastases from breast cancer: towards a management guideline. Int J Surg. 2011;9:285–91. doi:10.1016/j.ijsu.2011.01.009.PubMedCrossRefGoogle Scholar
  23. 23.
    Anaya DA, Blazer DG, Abdalla EK. Strategies for resection using portal vein embolization: hepatocellular carcinoma and hilar cholangiocarcinoma. Semin Intervent Radiol. 2008;25:110–22. doi:10.1055/s-2008-1076684.PubMedCrossRefGoogle Scholar
  24. 24.
    Sturesson C, Keussen I, Tranberg KG. Prolonged chemotherapy impairs liver regeneration after portal vein occlusion – an audit of 26 patients. Eur J Surg Oncol. 2010;36:358–64. doi:10.1016/j.ejso.2009.12.001.PubMedCrossRefGoogle Scholar
  25. 25.
    Covey AM, Brown KT, Jarnagin WR, et al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg. 2008;247:451–5. doi:10.1097/SLA.0b013e31815ed693.PubMedCrossRefGoogle Scholar
  26. 26.
    Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN. Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol. 2008;15:2765–72. doi:10.1245/s10434-008-0035-7.PubMedCrossRefGoogle Scholar
  27. 27.
    Beal IK, Anthony S, Papadopoulou A, et al. Portal vein embolisation prior to hepatic resection for colorectal liver metastases and the effects of periprocedure chemotherapy. Br J Radiol. 2006;79:473–8. doi:10.1259/bjr/29855825.PubMedCrossRefGoogle Scholar
  28. 28.
    Tellez C, Benson 3rd AB, Lyster MT, et al. Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review of the literature. Cancer. 1998;82:1250–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Vogl TJ, Zangos S, Balzer JO, Thalhammer A, Mack MG. Transarterial chemoembolization of liver metastases: indication, technique, results. Rofo. 2002;174:675–83. doi:10.1055/s-2002-32228.PubMedCrossRefGoogle Scholar
  30. 30.
    Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140:497–507. doi:10.1053/j.gastro.2010.10.049.PubMedCrossRefGoogle Scholar
  31. 31.
    Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant. 2009;9:1920–8. doi:10.1111/j.1600-6143.2009.02695.x.PubMedCrossRefGoogle Scholar
  32. 32.
    Vogl TJ, Mack MG, Balzer JO, et al. Liver metastases: neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. Radiology. 2003;229:457–64. doi:10.1148/radiol.2292021329.PubMedCrossRefGoogle Scholar
  33. 33.
    Nosher JL, Ohman-Strickland PA, Jabbour S, Narra V, Nosher B. Changes in liver and spleen volumes and liver function after radioembolization with yttrium-90 resin microspheres. J Vasc Interv Radiol. 2011;22:1706–13. doi:10.1016/j.jvir.2011.08.017.PubMedCrossRefGoogle Scholar
  34. 34.
    Paprottka PM, Schmidt GP, Trumm CG, Hoffmann RT, Reiser MF, Jakobs TF. Changes in normal liver and spleen volume after radioembolization with (90)Y-resin microspheres in metastatic breast cancer patients: findings and clinical significance. Cardiovasc Intervent Radiol. 2011;34:964–72. doi:10.1007/s00270-011-0217-8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Hojjat Ahmadzadehfar
    • 1
  • Carsten Meyer
    • 2
  • Samer Ezziddin
    • 1
  • Amir Sabet
    • 1
  • Anja Hoff-Meyer
    • 1
  • Marianne Muckle
    • 1
  • Timur Logvinski
    • 2
  • Hans Heinz Schild
    • 2
  • Hans Jürgen Biersack
    • 1
  • Kai Wilhelm
    • 2
  1. 1.Department of Nuclear MedicineUniversity Hospital Bonn GermanyBonnGermany
  2. 2.Department of RadiologyUniversity Hospital BonnBonnGermany

Personalised recommendations